SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emmessar Biotech & Nutrition Ltd (524768) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 524768 NSE: | Pharmaceuticals & Drugs | Small Cap

Emmessar Biotech&Nut Share Price

25.92 0.42 (1.65%)
As on 05-May'26 16:59

Emmessar Biotech & Nutrition Ltd (524768)

BSE: 524768 NSE:
Key Metrics
Market Cap
₹13 Cr.
P/E Ratio
39.01
Price to Book (P/B)
1.60
Price to Sales (P/S)
34.63
EV/EBITDA
6.69
Return on Capital Employed (ROCE)
12.63%
Current Price
₹25.9
Return on Equity (ROE)
4.19%
Return on Assets (ROA)
3.48%
Operating Profit Margin
-155.5%
Net Profit Margin
51.76%
Gross Profit Margin
172.8%
Book Value per Share
₹16.2
Sales Growth (YoY)
8.93%
Sales Growth (3 Years)
19.22%
Operating Profit Growth (1 Year)
NA%
Operating Profit Growth (3 Years)
N/A%
Net Profit Growth (1 Year)
-57.33%
52-Week Low / High
₹18 / 43
Net Profit Growth (3 Years)
-12.71%
Dividend Yield
0.00%
Promoter Holding
59.53%
Pledged shares (%)
of Promoter's holding (%)
0.00%

Check Before You Invest

Q.1 Stock return of Emmessar Biotech & Nutrition Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 8.2% based on the current price.
Q.1 Revenue growth of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd revenue growth is 8.9% for FY-2025, which is above its 5-year CAGR of -29.08%, indicating faster growth.
Q.1 Which industry/sub-sector does Emmessar Biotech & Nutrition Ltd belong to?
Emmessar Biotech & Nutrition Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1 Promoter shareholding and pledge status of Emmessar Biotech & Nutrition Ltd?
Promoters hold 59.53% of the Emmessar Biotech & Nutrition Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Revenue growth of Emmessar Biotech & Nutrition Ltd vs industry peers?
Emmessar Biotech & Nutrition Ltd revenue CAGR is -29.08%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Emmessar Biotech&Nut

Based on:

M-Cap below 100cr DeciZen not available

Emmessar Biotech & Nutrition stock performance

Key Ratios
mw4me loader

Is Emmessar Biotech & Nutrition Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Emmessar Biotech & Nutrition Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -59.4%79.5%31.5%9%18.9%45.3%15.7%15%11.4%12.6%-
Value Creation
Index
-5.24.71.3-0.40.42.20.10.1-0.2-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 22.61.30.63.470.410.60.60
Sales YoY Gr.-33.5%-52.5%-49.6%439.7%105.6%-94.9%183.3%-45.1%8.9%-
Adj EPS 0.42.41.81.51.92.90.611.50.60.7
YoY Gr.-555.6%-22.5%-19.7%27.9%54.3%-79.7%69.5%50%-58%-
BVPS (₹) 1.84.2678.511.412.413.314.815.416.2
Adj Net
Profit
0.21.20.90.70.91.50.30.50.80.30
Cash Flow from Ops. 0.40.80.70.410.52.30.40.60.2-
Debt/CF from Ops. 0000.20000.20.20-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -12.2%-29.1%19.2%8.9%
Adj EPS 6.4%-19.6%2.2%-58%
BVPS26.8%12.6%7.7%4.1%
Share Price 8% 4.3% 2% -21.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
15.678.63622.624.129.157.810.74.24.2
Op. Profit
Mgn %
0.68.6-33.3-101.6-11.912.1-242.5-67.1-194.3-155.5-350.2
Net Profit
Mgn %
944.872.9116.527.620.780.949.2135.351.689.2
Debt to
Equity
0000000000-
Working Cap
Days
1751523339051931242,0443265124183,630
Cash Conv.
Cycle
64403918747571,3473884743,401

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials

Standalone Consolidated
TTM EPS (₹) 0.7 -
TTM Sales (₹ Cr.) 0.4 -
BVPS (₹) 16.2 -
Reserves (₹ Cr.) 3 -
P/BV 1.60 -
PE 39.01 -
From the Market
52 Week Low / High (₹) 18.42 / 42.90
All Time Low / High (₹) 1.00 / 64.00
Market Cap (₹ Cr.) 13
Equity (₹ Cr.) 5
Face Value (₹) 10
Industry PE 43.8

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Emmessar Biotech&Nut - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1.972.631.250.633.406.990.361.020.560.61
Operating Expenses + 1.962.411.671.273.806.141.261.711.641.56
Manufacturing Costs0.410.730.390.251.371.630.040.050.050.05
Material Costs10.980.630.121.543.530.130.400.200.18
Employee Cost 0.310.390.410.580.580.640.770.840.960.93
Other Costs 0.240.310.240.320.310.340.320.420.430.40
Operating Profit 0.010.23-0.42-0.64-0.400.85-0.89-0.69-1.08-0.95
Operating Profit Margin (%) 0.6%8.6%-33.3%-101.0%-11.9%12.1%-245.0%-67.6%-194.0%-155.0%
Other Income + 0.260.981.271.301.471.471.921.751.992.01
Exceptional Items -0.9200-0.29-0.2600000
Interest 00.0100000000
Depreciation 0.030.010.050.080.060.060.090.090.100.10
Profit Before Tax -0.681.180.800.290.742.250.930.970.810.96
Tax -0.210-0.12-0.24-0.020.800.460.460.060.64
Profit After Tax -0.471.180.910.530.751.450.480.500.750.32
PAT Margin (%) -23.6%44.8%72.9%84.7%22.2%20.7%130.3%49.4%135.0%51.8%
Adjusted EPS (₹)-0.92.41.81.11.52.91.01.01.50.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 0.912.092.983.514.265.706.176.667.407.71
Share Capital 5555555555
Reserves -4.09-2.91-2.01-1.49-0.730.701.171.672.412.71
Debt +0000.070000.080.110
Long Term Debt0000000000
Short Term Debt0000.070000.080.110
Minority Interest0000000000
Trade Payables0.200.200.010.580.800.500.0200.010
Others Liabilities 1.050.810.690.530.351.291.411.351.251.71
Total Liabilities 2.163.113.684.685.417.497.608.098.779.42

Fixed Assets

Net Fixed Assets +0.730.722.251.991.911.861.461.401.311.22
Gross Block1.311.302.882.632.602.602.022.042.042.04
Accumulated Depreciation0.580.580.630.640.680.740.560.650.740.82
CWIP 00.8000000000
Investments 0.010.010.010.010.010.010.010.010.010.01
Inventories0.360.320.090.731.150.070.070.140.090.12
Trade Receivables0.360.040.030.040.032.710.010.010.020.02
Cash Equivalents flag 0.430.320.270.711.882.474.585.196.186.87
Others Assets 0.270.891.031.210.440.381.471.351.161.17
Total Assets 2.163.113.684.685.417.497.608.098.779.42

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.440.750.740.391.030.472.270.380.640.22
PBT -0.681.180.800.5812.250.930.970.810.96
Adjustment 0.730.060.01-0.07-0.31-0.07-0.13-0.15-0.42-0.37
Changes in Working Capital 0.39-0.45-0.02-0.120.34-1.611.76-0.50.24-0.35
Tax Paid 0-0.04-0.0500-0.10-0.290.060.02-0.02
Cash Flow From Investing Activity + -0.46-0.74-0.69-0.37-1.060.01-2.61-0.55-0.64-0.23
Capex -0.02-0.01-0.78-0-0-0-0.31-0.0300
Net Investments -0-00.08-0.41-1.19-0.11-2.45-0.78-0.99-0.69
Others -0.44-0.740.010.040.140.120.140.260.350.46
Cash Flow From Financing Activity + 0000000000
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 000000000-0
Dividend Paid 0000000000
Others 0000000000
Net Cash Flow -0.020.010.050.01-0.030.48-0.34-0.170-0

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-40.7578.733616.4219.429.18.017.8510.664.19
ROCE (%)-59.3779.4631.46918.8745.2915.7114.9911.4212.63
Asset Turnover Ratio0.891.030.390.150.671.080.050.130.070.07
PAT to CFO Conversion(x)N/A0.640.810.741.370.324.730.760.850.69
Working Capital Days
Receivable Days3627.4010.3020.803.5071.401,361.904.2010.9012
Inventory Days93.3045.7056.20236.30100.9031.8067.8036.6074.1063.60
Payable Days9375.6061.20856.60163.3067.20752.50016.8012.50

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Emmessar Biotech & Nutrition Ltd FAQs

The current trading price of Emmessar Biotech&Nut on 05-May-2026 16:59 is ₹25.92.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-May-2026 the market cap of Emmessar Biotech&Nut stood at ₹12.95 Cr

The latest P/E ratio of Emmessar Biotech&Nut as of 04-May-2026 is 39.01.

The latest P/B ratio of Emmessar Biotech&Nut as of 04-May-2026 is 1.60.

The 52-week high of Emmessar Biotech&Nut is ₹42.90 and the 52-week low is ₹18.42.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Emmessar Biotech&Nut is ₹0.37 ( Cr.) .

About Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Ltd., was originally started as Emmessar Chemical Industries Ltd on  March 17,1992, for manufacturing Super Speciality Fine Chemicals. The Company succeeded in developing many Speciality Fine Chemicals in its own In-house R&D, which was recognised on  January 15, 1996 by DSIR, Ministry of Science & Technology, Government of India, New Delhi .

When there was a realisation that some of the Speciality Chemicals developed in our R&D and exported to USA & Europe were being used in Healthcare formulations, the Company decided to re-orient itself and enter the Healthcare business, which is poised for phenomenal growth in the coming decades.

Concurrently the company also realised that some of the Speciality Chemicals are actually Vital Micro Nutrients, which are being used in the research worldwide as tools of Biotechnology, the Company took a conscious decision to enter the field of Biotechnology & Healthcare.

To ensure that the name is representative of its activity, the company's name was changed from Emmessar Chemical Industries Ltd., to Emmessar Biotech & Nutrition Ltd., on 7th April 2000.

In the process of pursuing its own R&D and exploring commercial market potentials for their products in the field of Healthcare, the company came across another reputed company in USA Vibrant Life in California.

Intense exchange of ideas & technical information between Emmessar Biotech & Nutrition Ltd., & Vibrant Life, resulted in development of several new concepts and new technologies - combining different schools of thought such as Nutraceuticals, Cosmeceuticals, Ayurveda & Biotechnology.

The company has developed many products covering different areas of healthcare that include obstinate Skin problems & debilitating chronic physical ailments.

Emmessar Biotech & Nutrition Ltd., is a Public Limited Company, with the Paid-up Share Capital of about Rs. 50.00 million (over $ 1.00 million). The Stocks of Emmessar Biotech & Nutrition Ltd., are traded in The Bombay Stock Exchange Ltd.

Product range of the company includes:

Present products

  • Calmcream 
  • Magicream 
  • Supportt Joint  
  • Supportt Bones
  • Micro Nutrients 
  • Speciality Chemicals
  • CC-99  
  • Biosulf  
  • Calmcream  

Products planned to be launched in future

  • Ayurvedic Creams  
  • Nutraceutical Creams
  • Cosmeceutical Creams  
  • Oral Supplements  
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×